Element Biosciences, Inc. has announced an upsized Series E funding round, securing $175 million from Samsung Electronics and additional undisclosed investors. This investment will accelerate the commercialization of Element's genomic and multiomic technologies, including the AVITI platform and the newly introduced VITARI high-throughput benchtop system. The funding will also support the upcoming launches of AVITI Dx and tissue profiling on AVITI24. With this capital, Element aims to expand its global presence and enhance its product offerings across research, translational science, and diagnostic applications. Since the launch of AVITI in 2022, Element has broadened its portfolio, allowing researchers to gain deeper biological insights through integrated analyses. The company has established a customer base in over 40 countries across various sectors, including academia and pharmaceuticals. CEO Molly He highlighted that this financing is a significant endorsement of their technology and vision, especially during a challenging market environment. The funding is subject to regulatory approval and follows a prior $277 million Series D round announced in July 2024.